As­traZeneca, Mer­ck her­ald PhI­II prostate can­cer win for Lyn­parza — over­tak­ing Clo­vis, J&J in PARP race

The case for ex­pand­ing Lyn­parza’s use just got stronger as As­traZeneca and Mer­ck claim a late-stage suc­cess in ex­tend­ing the time prostate can­cer pa­tients live …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER